Oral
Type 2 diabetes mellitus
Adult: Each immediate-release tab contains pioglitazone 15 mg and metformin 500 mg or pioglitazone 15 mg and metformin 850 mg: Initially, 15 mg/500 mg bid or 15 mg/850 mg once daily. Patients inadequately controlled on metformin monotherapy: Initially, 15 mg/500 mg bid or 15 mg/850 mg 1-2 times daily, depending on current metformin dose. Patients inadequately controlled on pioglitazone monotherapy: Initially, 15 mg/500 mg bid or 15 mg/850 mg once daily. Max: Pioglitazone 45 mg and metformin 2,550 mg daily. Each extended-release tab contains pioglitazone 15 mg and metformin 1,000 mg or pioglitazone 30 mg and metformin 1,000 mg: Initially, 15 mg/1,000 mg or 30 mg/1,000 mg once daily. Patients inadequately controlled on metformin or pioglitazone monotherapy: 15 mg/1,000 mg bid or 30 mg/1,000 mg once daily. Max: Pioglitazone 45 mg and metformin 2,000 mg daily. Doses may be titrated gradually according to response.
Renal impairment:
CrCl (ml/min) | Dosage Recommendation |
<60 | Contraindicated. |
Special Populations: Patient taking pioglitazone and metformin w/ an insulin secretagogue (e.g. sulfonylurea): Decrease insulin secretagogue dose. Patient taking pioglitazone and metformin w/ insulin: Decrease insulin dose by 10-25%. Patient taking pioglitazone and metformin w/ strong CYP2C8 inhibitors: Max: 15 mg/850 mg daily (immediate-release tab) or 15 mg/1,000 mg daily (extended-release tab).